MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation P/CF Ratio 2011-2026 | NVTA
Annual P/CF Ratio Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.04 | -4.24 | -22.3 | -10.8 | -9.52 | -3.11 | -3.13 | -2.27 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.04 | -22.3 | -7.05 |
P/CF Ratio of other stocks in the Diagnostics research industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
26.1 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
28.3 | $ 111.3 | -3.12 % | $ 33.8 B |  USA |
|
Akumin
AKU
|
1.15 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-0.447 | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
-1.41 | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-0.826 | - | -61.36 % | $ 2.46 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.5 | $ 25.58 | -5.68 % | $ 20 B |  Niderland |
 |
CareDx, Inc
CDNA
|
23.6 | $ 20.8 | -5.07 % | $ 1.11 B | USA |
 |
Chembio Diagnostics
CEMI
|
-0.991 | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-47.7 | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-0.541 | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-0.201 | $ 1.53 | -6.13 % | $ 2.04 M | USA |
 |
Castle Biosciences
CSTL
|
10.9 | $ 24.24 | -1.86 % | $ 673 M | USA |
 |
DermTech
DMTK
|
-0.551 | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
0.396 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-17.1 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-1.63 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-2.94 | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
10.4 | $ 163.84 | -1.77 % | $ 8.12 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
21.8 | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
-0.00219 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
39.7 | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-72.7 | $ 83.41 | 0.35 % | $ 10.5 B | USA |
 |
Fulgent Genetics
FLGT
|
22.2 | $ 14.8 | -3.27 % | $ 447 M | USA |
 |
Heska Corporation
HSKA
|
-38.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-0.162 | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
1.26 | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
Illumina
ILMN
|
19.6 | $ 120.37 | -5.16 % | $ 19.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
12.6 | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
-1.87 | $ 2.16 | -1.22 % | $ 4.96 M | USA |
 |
Lantheus Holdings
LNTH
|
13.1 | $ 81.17 | -2.85 % | $ 5.48 B | USA |
 |
ICON Public Limited Company
ICLR
|
12.9 | $ 116.17 | 13.35 % | $ 9.58 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
14.6 | $ 257.14 | -0.94 % | $ 21.4 B | USA |
 |
Medpace Holdings
MEDP
|
18.2 | $ 413.59 | 0.93 % | $ 11.9 B | USA |
 |
Celcuity
CELC
|
-35 | $ 119.0 | -0.89 % | $ 5.56 B | USA |
 |
Motus GI Holdings
MOTS
|
-0.0884 | - | -34.28 % | $ 263 K | Israel |
 |
NeoGenomics
NEO
|
284 | $ 8.96 | -0.67 % | $ 1.15 B | USA |
 |
Neogen Corporation
NEOG
|
17.5 | $ 9.01 | -3.53 % | $ 1.95 B | USA |
 |
National Research Corporation
NRC
|
11.9 | $ 16.54 | -1.78 % | $ 370 M | USA |
 |
Myriad Genetics
MYGN
|
227 | $ 4.68 | -3.31 % | $ 433 M | USA |
 |
OpGen
OPGN
|
-1.87 | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
-12.3 | $ 194.75 | -2.71 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
12.4 | $ 189.32 | -2.94 % | $ 21 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-40.2 | $ 16.24 | -2.46 % | $ 175 M | China |
 |
Organovo Holdings
ONVO
|
-0.328 | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
22.5 | - | -0.91 % | $ 14.7 B | USA |
 |
Personalis
PSNL
|
-5.62 | $ 5.04 | -8.36 % | $ 299 M | USA |
 |
Precipio
PRPO
|
56 | $ 29.94 | -5.73 % | $ 48.1 M | USA |
 |
Exagen
XGN
|
-5.14 | $ 2.76 | 1.1 % | $ 59.5 M | USA |